TABLE III.

Denosumab versus zoledronate in patients with breast cancer and evidence of 1 or more metastatic bone lesions

Reference	Patients (n)	Endpoints	Results (95% ci)	p Value
Stopeck et al., 201043	2046	Time (months) to first on-study srea	hr: 0.82 (0.71 to 0.95)	<0.001b
				0.01c
		Time to first and subsequent on-study sre	rr: 0.77 (0.66 to 0.89)	0.001

^aDefined as pathologic fracture (excluding major trauma), radiation therapy to bone, surgery to bone, or spinal cord compression.

^bBy non-inferiority test.

^cBy superiority test.

ci = confidence interval; sre = skeletal-related event; hr= hazard ratio; rr = relative risk.